A Trial of Selinexor, Ruxolitinib and Methylprednisolone

Multiple Myeloma in Relapse Clinical Trial

— KPT-IST-391  

Official title:

A Phase I Trial of Selinexor, Ruxolitinib and Methylprednisolone for Patients With Relapsed/Refractory Multiple Myeloma

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06225310
• Other study ID #: KPT-IST-391
• Status: Not yet recruiting
• Phase: Phase 1
• Start date: March 1, 2024
• Est. completion date: May 1, 2027

Study information

• Verified date: January 2024
• Source: Oncotherapeutics
• Contact: Halle Hunt, MS
• Phone: (310) 623-1121
• Email: hhunt[@]oncotherapeutics.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Selinexor, a first-in-class, oral selective exportin 1 (XPO1) inhibitor, has shown promise in pre-clinical and clinical studies. It functions by inhibiting the nuclear export protein XPO1, resulting in the accumulation of tumor suppressor proteins and inhibition of oncoprotein mRNAs, which is selectively lethal to myeloma cells. Selinexor has demonstrated activity in combination with various drugs, including glucocorticoids and proteasome inhibitors, leading to its FDA approval for the treatment of relapsed or refractory multiple myeloma.

Description:

Selinexor, a first-in-class, oral selective exportin 1 (XPO1) inhibitor, has shown promise in pre-clinical and clinical studies. It functions by inhibiting the nuclear export protein XPO1, resulting in the accumulation of tumor suppressor proteins and inhibition of oncoprotein mRNAs, which is selectively lethal to myeloma cells. Selinexor has demonstrated activity in combination with various drugs, including glucocorticoids and proteasome inhibitors, leading to its FDA approval for the treatment of relapsed or refractory multiple myeloma.

Ruxolitinib, an oral JAK1/2 inhibitor, has been approved by the FDA for myelofibrosis treatment. Preliminary experiments have shown that Ruxolitinib, in combination with lenalidomide and dexamethasone, effectively inhibits MM cell proliferation. Additionally, the combination of Ruxolitinib and dexamethasone has demonstrated enhanced anti-MM effects. Clinical results indicate that Ruxolitinib in combination with steroids is well-tolerated in heavily treated MM patients.

This proposed study aims to investigate the efficacy of a lower dose of Selinexor in combination with Ruxolitinib and methylprednisolone for patients with relapsed/refractory multiple myeloma. The study builds on the existing evidence of the individual and synergistic effects of Selinexor and Ruxolitinib, both in preclinical and clinical settings and seeks to provide a potential new treatment option for MM patients.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 30
• Est. completion date: May 1, 2027
• Est. primary completion date: April 1, 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Patients must meet all the following inclusion criteria to be eligible to enroll in this study:

Patients with relapsed/refractory multiple myeloma with at least three prior regimens Received an

1. Anti-CD38 antibody

2. Immunomodulatory agent (IMiD)

3. And a proteasome inhibitor (PI) Age = 18 years of age.

• Willing and able to provide written informed consent in accordance with federal, local, and institutional guidelines. The patient must provide informed consent prior to the first screening procedure.

• Able to adhere to the study visit schedule and other protocol requirements.

• Have a diagnosis of MM according to IMWG diagnostic criteria:

Clonal bone marrow plasma cells >10% or biopsy-proven bony or extramedullary plasmacytoma and any one or mor of the following CRAB features and myeloma-defining events:

• Evidence of end organ damage that can be attributed to the underlying plasma cell proliferative disorder, specifically:

• Hypercalcemia: serum calcium >0.25 mmol/L (>1mg/dL) higher than the upper limit of normal or >2.75 mmol/L (>11mg/dL)

• Renal insufficiency: creatinine clearance <40 mL per minute or serum creatinine >177mol/L (>2mg/dL)

• Anemia: hemoglobin value of >20g/L below the lowest limit of normal, or a hemoglobin value <100g/L

• Bone lesions: one or more osteolytic lesion(s) on skeletal radiography, CT, or PET/CT. If bone marrow has <10% clonal plasma cells, more than one bone lesion is required to distinguish from solitary plasmacytoma with minimal marrow involvement

Any one or more of the following biomarkers of malignancy (MDEs):

• 60% or greater clonal plasma cells on bone marrow examination

• Serum involved / uninvolved free light chain ratio of 100 or greater, provided the absolute level of the involved light chain is at least 100mg/L (a patient's involved free light chain either kappa or lambda is the one that is above the normal reference range; the uninvolved free light chain is the one that is typically in, or below, the normal range)

• More than one focal lesion on MRI that is at least 5mm or greater in size.

Currently has MM with measurable disease, defined as:

• a monoclonal immunoglobulin spike on serum electrophoresis of at least 0.5 g/dL and/or urine monoclonal protein levels of at least 200 mg/24 hours

• for patients without measurable serum and urine M-protein levels, an involved SFLC > 100 mg/L or abnormal SFLC ratio

• for patients with IgD MM, a monoclonal immunoglobulin IgD of at least 5500 mg/L or meet other measurable disease eligibility criteria

• for patients with IgA MM, total IgA > 700 mg/dL

Currently has progressive MM: MM patients that are relapsed or have refractory disease from at least 3 regimens or lines of therapy are eligible for enrollment provided they fulfill the other eligibility criteria:

• patients are considered relapsed, when they progress greater than 60 days from their last dose of treatment

• patients are refractory when they progress while currently receiving the treatment or within 8 weeks of its last dose

Adequate hepatic function within 28 days prior to C1D1:

Total bilirubin < 1.5 × upper limit of normal (ULN) (except patients with Gilbert's syndrome who must have a total bilirubin of < 3 × ULN), and Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) normal to < 2 × ULN.

Adequate renal function within 28 days prior to C1D1 as determined by serum creatinine of =1.5 mg/dL OR estimated creatinine clearance (CrCl) of > 60 mL/min, calculated using the Cockcroft and Gault formula (140 - Age) • Mass (kg)/ (72 • creatinine mg/dL); multiply by 0.85 if female (12)(Appendix 5).

Adequate hematopoietic function within 7 days prior to C1D1: total white blood cell (WBC) count =1500/mm3, absolute neutrophil count (ANC) =1000/mm3, hemoglobin =8.5 g/dL and platelet count =75,000/mm3 (patients for whom <50% of bone marrow nucleated cells are plasma cells) or =50,000/mm3 (patients for whom =50% of bone marrow nucleated cells are plasma cells).

Patients receiving hematopoietic growth factor support, including erythropoietin, darbepoetin, granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF), and platelet stimulators (e.g., eltrombopag, romiplostim, or interleukin-11) must have a 2-week interval between growth factor support and the Screening assessments, but they may receive growth factor support during the study.

Patients must have:

• At least a 2-week interval from the last red blood cell (RBC) transfusion prior to the first day of study treatment

• At least a 1-week interval from the last platelet transfusion prior to the first day study treatment

• However, patients may receive RBC and/or platelet transfusions as clinically indicated per institutional guidelines during the study

Female patients of childbearing potential (FCBP) must have a negative serum pregnancy test at Screening. Female patients of childbearing potential and fertile male patients who are sexually active must use highly effective methods of contraception throughout the study and for one month following the last dose of study treatment. Male patients must agree not to donate sperm during the study treatment period. Specifically:

• FCBP† must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 10 - 14 days prior to and again within 24 hours of starting treatment and must either commit to continued abstinence from heterosexual intercourse or use acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, and at least 28 days before she starts therapy. FCBP must also agree to ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a vasectomy. All subjects must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure.

† A FCBP (female of childbearing potential) is a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months) Able to take aspirin (acetylsalicylic acid, ASA) at 81 or 325 mg/daily as antiplatelet therapy if platelet count is above 30 x 109/L and ECOG must be = 2 (subjects intolerant to ASA may use warfarin, low molecular weight heparin, or direct oral anticoagulants).

Patients with history of human immunodeficiency virus (HIV) are eligible if they have CD4+ T cell counts =350 cells/µL, negative viral load per institutional standard, and no history of acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections in the last year.

Patients with untreated hepatitis C virus (HCV) are eligible if there is a documentation of negative viral load per institutional standard.

Exclusion Criteria:

Patients meeting any of the following exclusion criteria are not eligible to enroll in this study:

1. Patients who had prior exposure to ruxolitinib or selinexor

2. Prior malignancy that required treatment or has shown evidence of recurrence (except for non-melanoma skin cancer or adequately treated cervical carcinoma in situ) during the 3 years prior to randomization. Cancer treated with curative intent for >5 years previously and without evidence of recurrence will be allowed.

3. Have light chain amyloidosis

4. Have plasma cell leukemia

5. Have history of active tuberculosis

6. Have any concurrent medical condition or disease (e.g., uncontrolled active hypertension, uncontrolled active diabetes, active systemic infection, POEMS syndrome [polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes], primary amyloidosis, etc.) that is likely to interfere with study procedures.

7. Uncontrolled active infection requiring parenteral antibiotics, antivirals, or antifungals within 1 week prior to Cycle 1 Day 1 (C1D1). Patients on prophylactic antibiotics or with a controlled infection within 1 week prior to C1D1 are acceptable.

8. Known intolerance, hypersensitivity, or contraindication to glucocorticoids.

9. Known hypersensitivity to compounds of similar chemical or biological composition to thalidomide and ruxolitinib or steroids.

10. Concurrent use of other anti-cancer agents or treatments.

11. The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs.

12. Severe hypercalcemia, i.e., serum calcium = 12 mg/dL (3.0 mmol/L) corrected for albumin

13. Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.

14. Pregnant or breastfeeding females.

15. Body surface area (BSA) <1.4 m2 at baseline, calculated by the Dubois or Mosteller method.

16. Life expectancy of less than 3 months.

17. Major surgery within 4 weeks prior to C1D1.

18. Active, unstable cardiovascular function, as indicated by the presence of:

1. Symptomatic ischemia, or

2. Uncontrolled clinically significant conduction abnormalities (e.g., patients with ventricular tachycardia on anti-arrhythmic are excluded; patients with first degree atrioventricular block or asymptomatic left anterior fascicular block/right bundle branch block will not be excluded), or

3. CHF of New York Heart Association Class =3 or known left ventricular ejection fraction < 40%, or

4. Myocardial infarction (MI) within 3 months prior to C1D1 or

5. Stroke and other thrombosis, such as, pulmonary embolism (PE) or deep vein thrombosis (DVT) within 3 months prior to C1D1.

19. Any active GI dysfunction interfering with the patient's ability to swallow tablets, or any active GI dysfunction that could interfere with absorption of study treatment.

20. Inability or unwillingness to take supportive medications such as anti-nausea and anti-anorexia agents as recommended by the National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines in Oncology (CPGO) (NCCN CPGO) for antiemesis and anorexia/cachexia (palliative care).

21. Any active, serious psychiatric, medical, or other conditions/situations that, in the opinion of the Investigator, could interfere with treatment, compliance, or the ability to give informed consent.

22. Contraindication to any of the required concomitant drugs or supportive treatments.

23. Patients unwilling or unable to comply with the protocol.

Related Conditions & MeSH terms

• Multiple Myeloma
• Multiple Myeloma in Relapse
• Multiple Myeloma, Refractory
• Neoplasms, Plasma Cell
• Recurrence

Intervention

Drug:
• Selinexor
Selinexor (KPT-330) is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in t
• Ruxolitinib
elective inhibitor of Janus kinase (JAK)
• Methylprednisolone
Glucocorticoid, steroid

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Oncotherapeutics

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Background and rationale for assessment of serum B cell maturation antigen levels (sBCMA)	Only for MM patients participating in the optional biomarker including sBCMA analysis study.; To evaluate the ability of MM-related biomarkers including sBCMA, to serve as: Diagnostic biomarker by determining specificity and sensitivity in MM patients; Prognostic biomarker by determining its ability to predict the probable course of the disease including its recurrence.; Stratification biomarker by examining its ability to predict clinical outcomes of MM patients	30 months
Primary	1. Maximum Tolerated Dose (MTD):	? A standard 3 + 3 dose escalation schedule will be used for all escalations	30 months
Primary	2. Recommended phase 2 dose (RP2D)		30 months
Secondary	1. Overall Response Rate ([ORR]=CR+VGPR+PR)		30 months
Secondary	2. Clinical Benefit Rate ([CBR]=CR+VGPR+PR+MR)		30 months
Secondary	3. To determine disease parameters for study treatment:	Time to progression (TTP) - define as the time from the initiation of therapy to progressive disease; Progression-free survival (PFS) - defined as the time from initiation of therapy to progressive disease or death from any cause, whichever occurs first; Time to first response - defined as the time from the initiation of therapy to the first evidence of confirmed clinical benefit defined as > minimal response (MR, including patients who achieved a complete response (CR), very good partial response (VGPR), partial response (PR), or MR; DOR - defined as the time from the first response to progressive disease; Overall survival (OS) - Overall survival, defined as the time from initiation of therapy to death from any cause or last follow-up visit	30 months